Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab …
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration approved MYLOTARG™ (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive …
MYLOTARG is a CD33-directed antibody-drug conjugate indicated for: treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults (1.1).
FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML
On September 1, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (Mylotarg, Pfizer Inc.) for the treatment of newly-diagnosed CD33-positive acute …
MYLOTARG™ (gemtuzumab ozogamicin) - Pfizer Medical …
MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients …
Development of Highly Optimized Antibody-Drug Conjugates against CD33 ...
Jan 15, 2021 · The reapproval of Mylotarg, an anti-CD33-calicheamicin antibody-drug conjugate (ADC), has provided a proof of concept for an ADC-based therapeutic for AML. Several other …
FDA approves Mylotarg for treatment of acute myeloid leukemia
The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express …
MYLOTARG™ Description - Pfizer Medical Information
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin [Ig] G4, kappa …
FDA approves gemtuzumab ozogamicin for CD33-positive AML …
On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARG, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive …
MYLOTARG™ Approved In The EU For The Treatment Of Previously ... - Pfizer
Pfizer today announced that the European Commission has approved MYLOTARG™ (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine for the treatment …
FDA Approval Summary: Mylotarg for Treatment of Patients with …
On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed or refractory …
- Some results have been removed